Abstract | Immune checkpoints arise from physiological changes during tumorigenesis that reprogramme inflammatory , immunological and metabolic processes in malignant lesions and local lymphoid tissues, which constitute the immunological tumour microenvironment (TME). Improving clinical responses to immune checkpoint blockade will require deeper understanding of factors that impact local immune balance in the TME. Elevated catabolism of the amino acids tryptophan (Trp) and arginine (Arg) is a common TME hallmark at clinical presentation of cancer. Cells catabolizing Trp and Arg suppress effector T cells and stabilize regulatory T cells to suppress immunity in chronic inflammatory diseases of clinical importance, including cancers. Processes that induce Trp and Arg catabolism in the TME remain incompletely defined. Indoleamine 2,3 dioxygenase (IDO) and arginase 1 (ARG1), which catabolize Trp and Arg, respectively , respond to inflammatory cues including interferons and transforming growth factor-β (TGFβ) cytokines. Dying cells generate inflammatory signals including DNA , which is sensed to stimulate the production of type I interferons via the stimulator of interferon genes (STING) adaptor. Thus, dying cells help establish local conditions that suppress antitumour immunity to promote tumorigenesis. Here, we review evidence that Trp and Arg catabolism contributes to inflammatory processes that promote tumorigenesis, impede immune responses to therapy and might promote neurological comorbidities associated with cancer.
Loss of cell growth control and increased cell sur vival are necessary but insufficient adaptations that precede malignant tumour formation, as benign pre malignant lesions develop in tissues of many people who do not get cancer 1 . In most people, inflammation associated with premalignant lesions activates local innate immune surveillance mechanisms that pre vent benign lesions from transitioning into malignant tumours 2 . In rare cases, cancer develops because local immune regulation becomes dominant, allowing pre malignant lesions to evade immune surveillance and form malignant tumours. Immune evasion occurs early in tumour development, in part by activation of immune checkpoints creating robust barriers to anti tumour immunity. How developing tumours evade immune surveillance is poorly understood, as it is diffi cult to detect premalignant lesions and determine their impact on local immune processes as well as draining lymphoid tissues.
At clinical presentation, immune checkpoints are well established and hint at pathways that promote immune evasion (Fig. 1) . At early stages of tumour development, local immune effector processes that mediate immune surveillance are overcome progressively by tolerogenic (immune regulatory) processes that become domi nant in malignant lesions and in tumour draining lymph nodes (TDLNs), which together constitute the immunological tumour microenvironment (TME). In essence, the TME is a site of chronic immune acti vation where immunogenic and tolerogenic processes are activated constitutively, reflecting Dvorak's 1986 comment that malignancies are "wounds that do not heal" 3 . Chronic immune activation provides growth factors that promote tumour growth and angiogenesis and suppresses antitumour immunity. Viewed from this perspective, therapeutic success depends on killing tumour cells, skewing local immune balance in favour of sustained dominance of immunogenic processes that kill tumour cells faster than they can be replaced and preventing re emergence of dominant tolerogenic pro cesses after therapy ceases. The final point is important because any tumour cells surviving initial therapy would benefit from a resurgent tolerogenic TME that nurtures tumour regrowth and metastasis.
Immune checkpoints
Mechanisms that suppress local immunity in inflamed tissues such as the tumour microenvironment.
Immunological tumour microenvironment
(TME). Primary tumour lesions and local draining lymph nodes where antitumour immunity is controlled.
Immune control by amino acid catabolism during tumorigenesis and therapy
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In this Review, we focus on increased local catabolism of the essential amino acid tryptophan (Trp), a common local feature that attenuates antitumour immunity in pri mary tumour lesions and TDLNs. Arginine (Arg) cata b olism has also been linked to suppression of antitumour immunity; however, as less is known about Arg catabo lism, and as its role in generating bioactive polyamines that impact cancer was discussed in a recent review 4 , we will discuss Arg only briefly here. Amino acid catabo lism is thought to reinforce immune checkpoints that suppress adaptive T cell immunity. Consistent with this notion, several drugs that act by different mechanisms to inhibit indoleamine 2,3 dioxygenase (IDO) enzyme activity, which catalyses the first step of Trp catabolism, have yielded encouraging clinical responses in initial phase II trials 5, 6 . However, the first IDO inhibitor drug to be studied in a phase III trial did not synergize with immune checkpoint inhibition (PD1 pathway blockade) to improve clinical outcomes in melanoma 7 , emphasiz ing the need for more research to understand how amino acid catabolism contributes to immune checkpoints that control immune balance during tumour development and following therapy.
Amino acids and tumour growth
As protein building blocks, amino acids are essential for tumour growth and for remodelling stromal and vascular architecture in the inflamed TME as tumours develop. Hence, it appears counterintuitive that elevated Trp and Arg catabolism would promote tumour growth. However, immune cells also need amino acids to expand and differentiate into effector cells capable of killing tumour cells. These considerations highlight the need for deeper understanding of how cells sense amino acids and adjust their functions accordingly when access to amino acids is limited. Suppressing immunity by catabo lizing Trp and Arg might be more important for tumour development than constraints on tumour growth owing to reduced access to these amino acids. Cells could also adapt to compensate for reduced amino acid access, for example, by upregulating amino acid transporters and tRNA charging enzymes. Of note, the Trp tRNAcharg ing enzyme (WARS) is uniquely induced by type II inter feron (IFNγ), suggesting that enhanced access to Trp might help cells survive in inflamed tissues 8 .
Amino acid catabolism activates cellular stress responses. Cells sense amino acids via two ribosomal kinases, the eIF2α kinase GCN2 and mTOR. When access to amino acids is limiting, GCN2 and/or mTOR activate and stimulate radical reprogramming of cell functions, leading to cell cycle arrest and autophagy. GCN2 senses binding of uncharged tRNA to ribosomes and shuts down mRNA translation and promotes cell autophagy, which releases amino acids and makes cells more resilient to nutrient stress 9 . GCN2 is required for optimal growth of sarcoma cells in mice and in culture, suggesting that the integrated stress response (ISR) driven In some people, local inflammatory processes associated with premalignant lesions promote immune regulatory (tolerogenic) processes that overcome immune surveillance and establish robust immune checkpoints at clinical presentation of cancer (purple boxes). Increasing rates of cell death and consequent release of damage-associated molecular patterns (DAMPs) such as cellular DNA are common features of developing tumour lesions, which may contribute to dominance of tolerogenic processes that promote tumour development. b | Changes in the inflammatory and immunological status of primary tumour lesions are accompanied by parallel changes in tumour-draining lymph nodes (TDLNs) that promote development of regulatory antigen-presenting cells (APCs) and regulatory T (T reg ) cells, which suppress generation of stimulatory APCs and helper and effector T cells. Elevated tryptophan (Trp) and arginine (Arg) catabolism may manifest in primary tumour lesions, in TDLNs or in both. Hence, effective cancer therapy must disrupt immune checkpoints to allow antitumour immunity to manifest and must also prevent re-emergence of tolerogenic processes following therapy that may cause tumour relapse. ARG1, arginase 1; IDO, indoleamine 2,3 dioxygenase.
by activated GCN2 promotes sarcoma growth 10 . mTOR is also required for optimal tumour growth in many models, although sensing amino acids is only one aspect of metabolic control by mTOR 11 . Dividing tumour cells must increase amino acid transport to make new pro teins, and several studies identified links between amino acid transporters, mTOR activity, metabolic reprogram ming and tumour growth [12] [13] [14] . In the mouse DBMA/TPA model of inflammatory skin carcinogenesis and a KRAS induced model of lung tumorigenesis, Ido1 gene expres sion was required for optimal tumour development 15, 16 . These genetic data reinforced pharmacological evidence that the IDO pathway inhibitor indoximod (also known as D1MT) could reverse the immune suppressive effects of IDO activity by inhibiting mTOR activation to promote cell autophagy via a GCN2independent mechanism 17, 18 . Tumour cells might compensate for reduced access to amino acids by upregulating expres sion of amino acid transporters and by modulating their sensitivity to amino acid sensors that activate GCN2 and mTOR signalling.
Initial indications that Trp catabolism promoted tumour growth emerged from studies in mice treated with IDO inhibitors, which slowed growth of subcuta neous Lewis lung carcinoma (LLC) and B16 melanoma tumour grafts and in autochthonous HER2 (also known as ERBB2)induced breast tumours [19] [20] [21] . In the subcu taneous tumour models, tumour cells did not express IDO, but tumour formation induced sustained eleva tion of IDO activity in dendritic cells (DCs) located in inflamed TDLNs
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. In the HER2 breast tumour model, IDO inhibitors were most potent when combined with DNA damaging radiotherapy or chemotherapy 20 , prompting substantial interest in targeting IDO as a novel approach to boost clinical responses after these treatments.
Inflammation induces IDO1 and ARG1
Tumour associated inflammation stimulates Trp and Arg catabolism, with consequences for tumour devel opment, therapy and comorbidities associated with some cancers (Fig. 2) . Increased cell death is a common feature of aseptic inflammation in the TME that gen erates damage-associated molecular patterns (DAMPs), including DNA. Microbial and mitochondrial DNAs are sensed by Toll like receptor 9 (TLR9), which is expressed by specialized antigen presenting cells (APCs) 23 . In con trast, many cells express cytosolic DNA sensors such as the nucleotidyltransferase cyclic GMP AMP synthase (cGAS), which activate the adaptor stimulator of inter feron genes (STING), a potent IFNβ inducer 24 . 25 . In contrast, TDO (also known as TDO2) gene expression responds to dietary intake in some liver cells and to glucocorticoid stress in other cells 26 . Increased Trp catabolism in patients with cancer might have adverse effects on mood and cause depres sion because Trp is the obligate precursor for synthe sis of the neurotransmitter serotonin (also known as 5hydroxytryptamine (5HT)) and the hormone mel atonin, which regulate mood and depressive behav iours. Moreover, some Trp catabolites are neuroactive, including quinolinic acid (QA), kynurenic acid (KA) and picolinic acid (PA) 27 . Arg is catabolized by argin ase 1 (ARG1) and nitric oxide synthetase (NOS). Nitric oxide is a vasodilator, impacts immune functions and inactivates IDO, as well as other enzymes containing haem cofactors 28 . The ARG1 product l ornithine can be converted into polyamines, which regulate cell pro liferation, and might influence tumour development and tumour immunity 4, 29 . IFNγ stimulates inducible NOS (iNOS), and T helper 2 (T H 2) cell type cytokines (IL4 and IL13) induce ARG1, while both IDO1 and ARG1 genes are responsive to the immunesuppressive cytokine TGFβ 30, 31 . Expression of IDO1 and TDO in tumours is of chief interest for therapeutic targeting, as elevated IDO1 and TDO expression manifests in many cancer types [32] [33] [34] [35] . Our unpublished analyses of public databases (KaplanMeier Plotter & The Human Protein Atlas) reveal that somewhat high IDO or TDO expression correlates with poor patient survival in some cancers (for example, lung cancer, gastric cancer and acute myeloid leukae mia (AML)) but not others (for example, breast cancer). However, enzyme activity was assessed in only a few studies, which is a key point, as gene expression might not enhance enzyme activity 33, 35 . IDO1 is often over expressed in tumour cells through genetic and epige netic mechanisms of pathogenic importance, such as RAS oncogene activation, pro inflammatory COX2 activation and BIN1 tumour suppressor inactivation 36 . Elevated IDO enzyme activity occurs in many human cancers, including those of the oesophagus, stomach, pancreas, colon, lung, breast, ovary, prostate, bladder, skin and brain [37] [38] [39] [40] [41] [42] , but it is not always clear if elevated IDO expression occurs in tumour, immune or stromal cells. IDO1 expression also correlated with poor clinical outcomes after therapy in multiple tumour types 39, 43, 44 . Although TDO is not expressed in immune cells, TDO elevation in tumour cells, for example, human glioblas toma cells, might promote immune suppression in the TME that increases tumour growth 45 . TDO elevation could also contribute to pathogenesis by non immune mechanisms in tumours such as breast cancer, where IDO1 expression is typically but not always absent 46, 47 . Some human tumours express both IDO1 and TDO 32 , and concerns that tumours might exploit TDO as an escape pathway prompted development of drugs that block both enzymes.
Trp and Arg catabolism affects T cells
Access to amino acids is necessary for resting (naive) T cells to proliferate and differentiate into effector cells. After stimulation, T cells rapidly upregulate an array of amino acid transporters, including SLC7A5. Ablating SLC7A5 blocked metabolic reprogramming via acti vation of mTOR and expression of the transcription factor MYC to prevent T cell proliferation 48 , revealing a critical need for enhanced amino acid access to sus tain T cell responses after priming. However, T cells have differential requirements for specific amino acids, as depletion of Trp or Arg activated GCN2 to block entry into S phase following T cell stimulation, while depletion of both isoleucine and leucine led to cell cycle entry (S-G1 transition), although T cells stopped dividing and died soon afterwards [49] [50] [51] . These distinc tive responses suggest that T cell access to sufficient Trp and Arg is a key signal required for cell cycle entry, while restricted access to other amino acids does not block cell cycle entry but causes catastrophic nutrient starvation soon after cell cycle entry. It may not be a coincidence that elevated Trp and Arg catabolism is a common TME hallmark. These adaptations could rep resent an evolved counter regulatory healing response to restrain immune mediated injury in inflamed tis sues where immune activation thresholds are reduced. Malignant lesions might hijack tissue healing responses to suppress antitumour immunity and create robust immune checkpoints.
Previous reviews describe how elevated Trp and Arg catabolism inhibits adaptive immunity by suppressing effector T cells and potentiating FOXP3lineage CD4 + regulatory T (T reg ) cell functions 33, 35 . In brief, tumour or stromal cells in malignant lesions catabolizing Trp and/or Arg suppress CD8 + effector T cells and stabilize T reg cells to protect tumour cells. Similarly, in TDLNs, APCs catabolizing Trp and Arg suppress expansion of conventional CD4 + helper T cells and tumour specific effector CD8 + T cells and stimulate and stabilize T reg cells (Fig. 1) . The combined actions of Trp and Arg depletion and Trp catabolite production at these discrete TME sites create robust barriers to antitumour immunity that complement immune checkpoints mediated by CTLA4 and PD1-PDL1 pathways in T cells. For exam ple, the PD1 and IDO pathways synergized to stabilize T reg cells in the B16 mouse melanoma model 52 . While PD1 signalling maintained PTEN activity to prevent PI3K activation, IDO activity activated GCN2 to block mTOR complex 2 (mTORC2) activation in T reg cells. These metabolic pathways synergized to suppress AKT signalling, thereby preventing destabilization of T reg cell regulatory functions in the inflamed TME. The dis tinctive roles of PTEN as a tumour suppressor in T cell acute lymphocytic leukaemia and a T reg cell stabilizer in the B16 melanoma model emphasize that a particular pathway can be active in multiple TME cell types and have differential effects on tumour growth or responses to therapy in specific models.
T reg cells can undergo reprogramming to provide helper or effector immune functions if they receive appropriate inflammatory signals. Physiological factors driving T reg cells to adopt diametric functions remain poorly defined but are important, as they will provide novel insights on how to improve clinical responses in patients with cancer by skewing the local immune bal ance in the TME in favour of immunogenic processes that target tumour cells. Because local Trp and Arg catabolism activates and stabilizes T reg cell functions, it follows that inhibiting these metabolic pathways might destabilize T reg cells to weaken a formidable barrier to antitumour immunity in the TME. For example, T reg cells unexpectedly provided helper functions to prime effec tive T cell responses to a tumour vaccine in naive mice, but T reg cell help was suppressed via an IDO dependent mechanism in mice with established B16 melano mas 53 . Stability might also differ among T reg cell subsets. In mice harbouring B16 melanomas, TDLN DCs expressing IDO activated a PD1 + T reg cell subset via a GCN2dependent mechanism to stabilize the transcrip tion factor EOS (also known as IKZF4), an obligate FOXP3 co repressor, and prevent T reg cell reprogram ming 54, 55 . Thus, the sensitivity of some T reg cells to Trp and Arg catabolism reveals potential targets to pro mote T reg cell reprogramming and to weaken immune checkpoints in patients with cancer.
Catabolism of Trp and Arg in the TME T cells and T reg cells respond to Trp and Arg catabo lism; thus, degradation of these amino acids by tumour or accessory cells expressing IDO, TDO and/or ARG1 regulate T cell immunity in the inflamed TME. This scenario, in which interactions between distinct cell types regulate immune balance in the TME, mirrors how accessory cells expressing PD1 ligands regulate T cell immunity. Some, but not all, tumour cells have elevated IDO, TDO, ARG1 and iNOS enzyme activity, and in some cases, resident stromal cells and/or infiltrat ing immune cells express these enzymes to promote Trp and Arg catabolism in the TME.
Monocytic cells that catabolize Trp and Arg.
Monocyte derived cells such as DCs and macrophages are innate immune cells with pivotal roles in promoting and reg ulating adaptive immunity. Owing to sustained inflam mation in the TME, monocyte derived cells found in the TME can exhibit distinctive phenotypes that differ from circulating peripheral blood monocytes (PBMCs) and APCs found in homeostatic tissues (Fig. 1) . For exam ple, in mice with subcutaneous B16 melanoma or LLC tumour grafts, a discrete DC subset with potent T cell regulatory attributes (DC regs ) exhibited IDO1 activity in TDLNs and displayed features of both B cells and plas macytoid DCs 22, 56 . Some DCs generated from human PBMCs can also express IDO1 and regulate T cell immu nity in response to inflammatory signals 57, 58 . Moreover, elevated numbers of IDO1expressing DCs were observed in sentinel lymph nodes from some patients with melanoma 59 , consistent with the notion that TDLN DCs expressing IDO1 regulate T cell immunity in some patients with cancer.
Myeloid derived suppressor cells (MDSCs) with macrophage and granulocyte-neutrophil attributes infil trate many primary tumour lesions in humans and mice. MDSCs often express ARG1, reflecting their potential origin as alternatively activated M2 macrophages 60, 61 . Some MDSCs also exhibit other immune regulatory hallmarks, including IL10, TGFβ and IDO 16 . In mice and humans with melanoma, IDO activity in tumour cells promoted MDSC recruitment and activation via a T reg cell dependent mechanism in the TME 16, 62 . Accordingly, IDO inhibition reduced MDSC and T reg cell numbers and diminished their regulatory functions. Increased numbers of circulating MDSCs expressing ARG1 were also observed in patients with glioblastoma 63 . Fibrocytes that expanded and circulated among PBMCs in patients with cancer also suppressed mitogen activated T cell proliferation ex vivo, primar ily via IDO, unlike circulating fibrocytes from healthy donors that potentiated T cell proliferation 64 . Thus, DCs, MDSCs and circulating fibrocytes catabolizing Trp and Arg mediate tolerogenic processes in the TME. Collectively, these inflammatory cells contribute to bar riers to natural and therapy induced antitumour immu nity, even if tumour cells themselves do not catabolize Trp or Arg.
DNA sensing and Trp catabolism DNA from dying cells is a potent immune tolerogen. Elevated Trp and Arg catabolism is a common feature of the TME in humans and mice, but mechanisms linking tumour growth to increased Trp and Arg catabolism are poorly understood. Inflammatory pathways are strong candidates, as inflammatory cytokines stimulate IDO1, ARG1 and iNOS expression (Fig. 2) . Moreover, some DCs in mice and humans express IDO in response to inter ferons and suppress T cell responses 57, 58, 65 . Further hints emerged from studies on immune responses to DNA nanoparticles and apoptotic (dying) cells in mice [66] [67] [68] [69] [70] 
Cell death influences immune balance in the TME.
Other potential factors that could influence immune responses to DNA during tumorigenesis include dif ferential rates and modes of tumour cell death, DNA release, uptake or sensing of DNA by cells in the TME and redundant requirements for IDO to promote tumour outgrowth. Studies on DNA sensing by mouse bone marrow derived macrophages (BMDMs) under score the ability of DNA to drive immune responses in opposing directions. While phagocytic BMDMs that ingested dying tumour cells sensed DNA to activate STING and trigger production of pro inflammatory cytokines 74 , BMDMs that ingested apoptotic thymocytes sensed DNA via TLR9, a microbial and mitochondrial DNA sensor, to induce potent tolerogenic responses 75 . Such diametric immune responses to DNA emphasize the need to better understand how distinct cell types in the TME sense DNA to enhance Trp catabolism and to optimize the use of IDO inhibitors to improve clinical responses to DNA damaging chemotherapies or radiotherapies. Similar considerations may apply to other DAMPs that promote innate immunity. In particu lar, DAMPs that stimulate type I interferon production may induce IDO1 activity downstream, although other DAMPs that induce IFNγ, IL10 or TGFβ production could also enhance Trp and/or Arg catabolism 30, 76 . Collectively, these observations underscore the critical role of DNA sensors and other DAMP sensors that acti vate inflammatory signalling pathways and influence immune balance in the developing TME. Moreover, recognition that DNA could promote tolerogenic or immunogenic responses in the TME has implications for cancer therapies using STING agonists.
Roles of Trp catabolites
Some Trp catabolites made downstream of IDO sup press immunity, and other Trp catabolites are neuro toxic (Fig. 3) . Thus, elevated Trp catabolism not only could attenuate antitumour immunity but also might cause undesirable neurological changes during cancer development or promote neurotoxicities in response to cancer treatment. . AHR signalling regulates immunity and induces some DCs to express IDO [77] [78] [79] [80] [81] . Thus, Kyn and KA might amplify IDO activity via AHR signalling and promote tolerogenic processes in the TME, a paradigm supported by a study on human cancers expressing IDO 82 . AHR signalling has multi ple links with cancer, including regulation of oncogene expression, angiogenesis and cell survival, as well as effects on immune cell functions 83 . One study showed that inhibition of the IDO pathway with indoximod stimulated immune responses via an AHR dependent mechanism in mesenchymal stem cells (MSCs) 84 , sug gesting that the antitumour effects of indoximod may in part depend on AHR activation in the TME, as well as IDO pathway modulation. The interface between Trp catabolism and AHR signalling provides numerous opportunities to modify the TME for clinical benefit, but the central role of AHR signalling in toxic responses to xenobiotic compounds such as dioxin, a synthetic AHR agonist, may be a limiting factor 85 . Downstream of Kyn, 3hydroxykynurenine (3HK) and 3hydroxyanthranilic acid (HAA) are also immune suppressive. HAA inhib ited pyruvate dehydrogenase kinase (PDK1) and NF κB activation to block T cell proliferation, promote T cell apoptosis and activate T reg cells, although how T cells and T reg cells sensed HAA is unclear 86, 87 . These studies were not performed in cancer models, and it is not known if 3HK and HAA condition the TME to promote tumour growth and, if so, via which mechanisms. A recent study revealed a metabolic link between Trp catabolism and tetrahydrobiopterin (BH4) synthesis in T cells, as the Trp catabolite xanthurenic acid (XA) inhibited the BH4 syn thesis required to generate effector T cells 88 . BH4 sup plementation overcame XA mediated suppression to boost antitumour immunity in mice, suggesting that IDO activity in the TME might block BH4 synthesis in T cells to attenuate antitumour immunity.
The previous points raise a key issue: TME cells express enzymes that further degrade specific Trp catab olites, making it difficult to ascertain which Trp catabolites mediate specific biological effects that impact tumour development, therapy or associated comorbid ities. For example, IFNγ induced human glioma cells to upregulate IDO1, IDO2 and other genes encoding enzymes in the pathway (KMO and KYNU) but down regulated others (ACMSD and KATII (also known as AADAT)) 89 . In this study, Kyn:Trp ratios were elevated in serum samples from patients with glioma (consist ent with elevated IDO activity) but KA, QA and PA levels were all reduced relative to healthy individuals. These observations implicate Trp catabolism in glioma pathogenesis but also reveal the difficulty of correlating data on gene expression in tumour cell lines with met abolic effects caused by Trp catabolism in patients with cancer. Another study in patients with glioma showed that QA from brain microglial cells was converted via QPRT expressed in glioma cells into the oxidized form of NAD + , which inhibits apoptosis and increases resistance to oxidative stress and might contribute to glioma sur vival via these processes 90 . Moreover, chemotherapy and radiotherapy enhanced QPRT expression by glioma cells, which might reinforce glioma cell protection in response to these therapies. Our unpublished analyses (using the Kaplan-Meier Plotter online tool) of genes encoding specific enzymes in the Trp catabolism path way reveal several positive and negative correlations with survival in patients with cancer, but no uniform picture emerges that applies to multiple cancers. Clearly, elevated Trp catabolism impacts tumour growth, antitu mour immunity and therapeutic responses in complex ways, and improved methods to assess metabolic flux downstream of IDO are needed to understand how Trp catabolism mediates immune suppression and other processes relevant to cancer. Delivering recombinant enzymes that function downstream of IDO to reduce levels of immune suppressive Trp catabolites in the TME is a potential strategy to improve antitumour immunity. For example, administering recombinant, PEGylated kynureninase (KYNU) to reduce Kyn levels in the TME attenuated immune suppression and promoted more effective tumour control in several mouse models when combined with immune checkpoint inhibitors or a cancer vaccine 91 . Lower Kyn levels may be beneficial because Kyn (and/or downstream catabolites) mediates immune suppression and neurotoxicity, although it may prove more challenging to reduce Kyn levels to those that promote clinical responses in patients.
Elevated Trp catabolism and cancer comorbidities. As in other chronic inflammatory syndromes, many patients with cancer suffer chronic pain, depression, behavioural disorders and fatigue, and some cancer treatments exacerbate these comorbidities 92 . Elevated Trp catabo lism in the TME might contribute to these neurological comorbidities, as some Trp catabolites are neuroactive (Fig. 3) . Targeting specific enzymes might help alleviate comorbidities associated with some cancers and cancer treatments such as chronic pain and depression. Trp is the obligate substrate for 5HT synthesis, and 5HT is an IDO substrate. Hence, sustained Trp catabolism reduces 5HT levels by removing Trp and degrading 5HT with consequent negative impacts on mood and behaviour 93 . Moreover, targeting Trp catabolism to treat neurologi cal dysfunction in patients with cancer might also help treat tumours, as many cancer cells and cell lines express 5HT receptors, and 5HT signalling impacts tumour growth, metastasis and angiogenesis 94, 95 . Elevated Trp catabolism during chronic inflammation in cancer and other conditions may cause neurological dysfunction owing to sustained production of neuroac tive Trp catabolites 96, 97 . QA and KA potentiate and antag onize, respectively, N-methyl-d-aspartate receptor signalling (NMDAR signalling) in neurons. In mice, genetic ablation of IDO1 prevented the increase in mechanical nociception caused by chronic inflammation in models of lipopoly saccharide induced arthritis and virus infections, while Kyn enhanced mechanical nociception in mice lacking the Ido1 gene 96, 97 . Thus, elevated Trp catabolism in the TME might impact neurological functions adversely before and after clinical presentation of cancer, and N-Methyl-d-aspartate receptor signalling (NMDAR signalling). A signalling pathway that has dichotomous effects on neurons such as promoting death or survival of neurons, resistance to trauma and synaptic plasticity and transmission.
Mechanical nociception
Perception of pain in response to a mechanical stimulus.
www.nature.com/nrc therapy could alleviate or potentiate these effects 98 . Strategies to manipulate Trp catabolites, especially in the central nervous system, might reduce these comor bidities in patients with cancer. However, fatigue and pain were common adverse effects observed in a phase I trial with the IDO inhibitor epacadostat (also known as INCB024360), although it is unclear how effective this drug was in reducing Kyn levels, as it has a relatively short half life (2-4 h) 99 .
Trp and Arg catabolism in therapy
The IDO pathway is an attractive target for intervention, as it affects multiple downstream pathways controlling cell growth, function and viability (Fig. 2) . Recent reviews provide detailed discussion of IDO inhibitors in clin ical development 36, 100 . Here, we offer a brief summary of efforts to target IDO and TDO pathways with small molecule inhibitors focusing on the compounds most studied in the clinic. To aid discussion, 
STING agonists and Trp catabolism in cancer therapy.
High type I interferon expression in tumour lesions correlates with spontaneous T cell priming by develop ing tumours 101 . In immunogenic tumour models such as B16 melanoma expressing a neoantigen (B16.SIY), this correlation occurs because DNA sensors acti vate STING dependent type I interferon signalling to enhance antigen cross presentation by CD8 + DCs, which primes robust antitumour immunity mediated by CD8 + T cells 102, 103 . These observations led to studies using syn thetic cyclic dinucleotides (CDNs) that bind and activate STING as anticancer therapeutics. Intratumoural injec tion of CDNs induced tumour regression and systemic antitumour immunity in mouse models of melanoma and colon and breast cancer 104, 105 . However, half of the mice failed to respond to CDN treatment and eventually succumbed to tumour growth. In addition, therapeutic responses were only partially dependent on type I inter feron signalling, suggesting that other pro inflammatory pathways might also promote immunogenic responses to CDNs. Although the antitumour effects of CDNs were not influenced by tumour immunogenicity, the require ment for STING to slow tumour growth manifested only if high numbers of B16.SIY cells were implanted 22, 102, 104 . This suggests that tumour burden and immunogenicity might impact how STING signalling influences immune balance in the TME. Studies in the LLC model support this notion, as parental LLC tumours grew slower and LLC cells expressing neoantigens grew faster in STING deficient mice 22 . Thus, CDN treatments might control highly immunogenic ('hot') tumours more effectively because immune checkpoints that regulate antitu mour immunity are less potent in these settings. How CDNs were administered to mice was also critical, as systemic CDN administration induced IDO activity in many mouse tissues; indeed, systemic CDN admin istration is an effective treatment to alleviate autoim mune arthritis and encephalitis in mice via IDO 70, 106 . These issues are clinically important because effective cancer immunotherapy must shift immune balance in the TME in favour of sustained dominance of immuno genic processes by disrupting established tolerogenic processes and -equally important -preventing sub sequent reemergence of tolerogenic processes after therapy (Fig. 1) .
Immune balance and adverse responses to therapy. The paradigm that effective cancer immunotherapy must reorient the immune balance in the TME raises several concerns. First, immunotherapy might shift immune balance too far, eliciting adverse toxicities owing to enhanced immunity such as autoimmunity, a toxicity that manifests in some patients after immune checkpoint therapy 107, 108 . Exacerbation of pre existing autoimmune diseases after checkpoint immunotherapy has also been reported 109, 110 . Second, chemotherapy, radio therapy and STING agonist treatments might stimulate tolerogenic responses that attenuate desired immunogenic responses. Notably, the efficacy of cyto toxic drugs is enhanced by IDO enzyme blockade in mice 20,21,111 , perhaps via STING agonism 105 . Poor clin ical responses to some TLR ligands and tumour vac cines might arise in part because increased IDO activity dampens the innate immune adjuvant effects of these treatments 112, 113 . Similarly, interferons might have had limited efficacy as cancer therapies, and in some cases they have increased tumour aggression, promoted metastasis and induced substantial adverse toxicities, perhaps in part because they induced IDO, which atten uated clinical benefit [114] [115] [116] . Lastly, neurological comor bidities associated with some cancers (for example, pain, altered behaviour and fatigue) and many cancer therapies (for example, neuropathy and 'chemo brain') might be linked mechanistically to elevated Trp catabo lism, which can generate neurotoxic catabolites (Fig. 3) . These considerations suggest that combining STING agonists with IDO inhibitors might be more effective and less toxic than monotherapies using one drug type. Moreover, this drug combination might be a more potent immunometabolic adjuvant to enhance anti tumour responses than traditional cytotoxic therapies or immunotherapy (for example, PD1 or PDL1 check point inhibitors), even when these latter treatments are combined with IDO inhibitors.
Cancer therapies targeting Trp catabolism.
The two most advanced drugs in development are indoximod and epacadostat. Preliminary reports relating to other drugs being tested in ongoing clinical trials include the IDO1 and TDO2 inhibitor navoximod (NLG919), which is approximately tenfold more selective as an IDO1 than a TDO inhibitor 117, 118 , the selective IDO1 inhibitor BMS986205 (REF. 119 ), the IDO1 and TDO2 inhibitor PF06840003 (REF. 120 ), the IDO1 inhibitor KHK2455
(REF.
121
), the indoximod pro drug NLG802 (REF.
122
), the IDO1 inhibitor LY3381916 and the IDO1 and TDO2 inhibitor SHR9146. As a class, these drugs exhibit lit tle efficacy as single agents, and toxicity is limited and manageable. Combination drug trial designs are being evaluated given the strong rationale for using IDO inhibitors as immunometabolic adjuvants to enhance NAtuRe Reviews | CAnCER To date, clinical evaluation of IDO inhibitors for cancer treatment has been driven largely by intense interest in identifying agents that improve the efficacy of immune checkpoint therapies, in particular, anti PD1 therapy. However, potent effects in preclinical tumour models were observed when IDO inhibitors were com bined with immunogenic cytotoxic chemotherapy 20 . The rationale for combination immunotherapy is based on the potential for multiple immune checkpoints to be active at clinical presentation and/or to suppress com pensatory responses to monotherapies targeting a single checkpoint or conventional cytotoxic therapies 123, 124 . In addition, evidence from preclinical models shows that IDO inhibitors can enhance immune checkpoint therapy [125] [126] [127] . Encouraging but preliminary phase I/II data have emerged from studies combining PD1 or PDL1 pathway inhibitors with indoximod for advanced mela noma [128] [129] [130] ; epacadostat for urothelial carcinoma 131 , renal cell carcinoma 132 , non small cell lung cancer (NSCLC) 133 and squamous cell carcinoma of the head and neck 134 ; BMS986205 for various advanced cancers 119 ; and navoximod for advanced solid tumours 135 . However, data from the first phase III trial (ECHO301) reported for anti PD1 and epacadostat in metastatic melanoma revealed that epacadostat did not enhance therapeutic responses to PD1 blockade 136 . Notwithstanding criticism of this phase III trial 7 and promising outcomes in early phase trials 6 , the disappointing outcome emphasizes the need for more biomarker analyses and improved mechanistic understanding of how T cell and metabolic immune checkpoints interact and compensate for each other during therapy.
Cytotoxic chemotherapies and targeting Trp catabolism. Many cytotoxic chemotherapies are immuno genic and can enhance immune responses 137 . As noted above, IDO inhibitors synergize powerfully with immunogenic chemotherapy and enhance the efficacy of radiotherapy 20, 21, 138 . Clinical regimens of immuno chemotherapy or immunoradiotherapy that include IDO inhibitors are appealing in principle to take advantage of synchronous tumour cell death and tumour related antigen release 139 that may enhance antigen cross presentation by APCs to stimulate effector T cells in the TME. In a phase I study in patients with meta static breast cancer, the combination of indoximod and docetaxel was well tolerated with no additive toxicity and an objective response rate of 18% (4 of 22 patients with partial responses) and an additional 45% (10 of 22 patients) achieving at least transient stable disease 140 ; however, results from a follow on randomized, placebo controlled phase II trial are not yet available. Other early phase combination drug trials are studying indoximod in combination with gemcitabine and nab paclitaxel for metastatic pancreatic cancer 141, 142 ; temozolomide with or without bevacizumab for temozolomide refractory glioblastoma 130 ; and cytarabine and idarubicin for newly diagnosed AML 143 . Additionally, a dedicated phase I pae diatric trial combining indoximod with temozolomide for patients with recurrent brain cancer or newly diag nosed diffuse intrinsic pontine glioma is ongoing 144, 145 . To date, all these combinations have been well tolerated with little indication of any overlapping toxicity with chemotherapy, but it is important to emphasize the preliminary nature of these early reports.
Radiation therapy and targeting Trp catabolism. Like many chemotherapies, radiation treatments induce a highly inflammatory milieu in targeted tissues in pre clinical studies 146 , including expression of interferons and other mediators that induce IDO. If potent cytotoxic and immunogenic effects of radiation are combined with IDO inhibitor therapy to enlist targeted immune responses to residual tumour cells, it may be possible to craft less toxic radiation strategies that retain effectiveness with reduced off target radiation exposure 144 . A recent preclinical study encourages immunoradiotherapy strat egies incorporating anti PD1 as well as IDO inhibition 147 . Another potential benefit of combining immunotherapy with radiation is the possibility of achieving abscopal responses, where local radiation delivered to one tumour may lead to regression in a distant tumour outside the radiation field [148] [149] [150] [151] . Abscopal responses to radiotherapy may be immune mediated and may reflect high grade immune priming. To date, clinical studies have combined IDO inhibitor therapy (indoximod) with radiosurgery for 130 and paediatric recurrent brain cancers or newly diagnosed pontine glioma 144, 145 . Preliminary results indicate that this combination was well tolerated when followed by cyclic immunochemo therapy using indoximod plus temozolomide. Using IDO inhibitors as immunometabolic adjuvants to radio logical and cytotoxic treatment modalities may enhance immune responsiveness with little added toxicity.
Trp catabolism and cancer biomarkers. Recent clin ical findings suggest that biomarker analyses will be critical to determine how IDO inhibitors can be used most effectively. Excitement in the field of cancer immu notherapy has encouraged aggressive entry to large (phase III) trials that, in retrospect, appears premature 7 . For example, tumour lesions often generate nitric oxide (possibly owing to iNOS activity), which inhibits IDO activity 28 , emphasizing the critical importance of meas uring IDO activity. However, few studies have evaluated IDO activity before and after therapy but instead rely on assessing IDO gene or protein expression. Systemic IDO activity was evaluated by assessing levels of Trp and Kyn in serum samples from patients with NSCLC before, during and after patients received radiotherapy 152 . While many (65%) patients with low serum IDO activity before and after radiotherapy were alive 10 years after radiotherapy, all patients with NSCLC with relatively high serum IDO activity succumbed within 3 years. Furthermore, IDO activity was reduced during radio therapy in most patients with NSCLC, but IDO activ ity levels increased after radiotherapy in some patients. These findings reinforce the notion that IDO activity contributes to immune checkpoints, show that radio therapy disrupts this barrier to clinical responses (albeit only transiently in some cases) and suggest that systemic measurements of IDO activity might be an informative biomarker of clinical responsiveness to radiotherapy in some patients with cancer.
Conclusions and future directions
Extensive evidence supports the notion that elevated Trp and Arg catabolism contributes to immune regulation that promotes tumour growth and therapy resistance. Targeting these biochemical pathways in patients with cancer offers promise, and many drugs are under devel opment with this goal in mind. However, setbacks in a recent clinical trial reveal the need for more research to better understand how changes in amino acid transport ers, sensors and catabolism impact immune responses in the TME. Biochemical changes associated with increased Trp and Arg catabolism have many effects on the function and viability of tumour, stromal and immune cells in the TME. Other outstanding questions are how Trp and Arg catabolism contributes to other immune regulatory mechanisms in the TME and how immune checkpoint blockade impacts Trp and Arg catabolism. There are also clear unmet needs to iden tify biomarkers of the potency of amino acid catabo lism in patients with cancer as ways to identify patients likely to benefit from treatments targeting amino acid catabolism. In this arena, biomarkers to inform patient recruitment to trials of IDO inhibitors, as well as to inform how best to use DNA damaging therapy plus PD1 inhibitors (or other immunotherapy) as an immu nometabolic adjuvant, are needed. Given the current focus on enhancing antitumour immunity, there is enor mous interest in gaining more understanding of how chronic inflammation associated with tumorigenesis stimulates local Trp and Arg catabolism that regulates immune responses. Furthermore, it will be important to identify innate and adaptive immune biomarkers for the stimulation of pathogenic Trp and Arg catabolism dur ing tumorigenesis as potential clues to the underlying fundamental processes of immune escape that promote cancer development or relapse after therapy.
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This study offers genetic evidence that IDO is crucial for tumour formation, vasculogenesis, metastasis and MDSC activation and recruitment. 
